- Home
- SRV vs PBYI Comparison
SRV vs PBYI Comparison
Compare SRV & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- PBYI
- Stock Information
- Founded
- SRV 2007
- PBYI 2010
- Country
- SRV United States
- PBYI United States
- Employees
- SRV N/A
- PBYI N/A
- Industry
- SRV Finance Companies
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SRV Finance
- PBYI Health Care
- Exchange
- SRV Nasdaq
- PBYI Nasdaq
- Market Cap
- SRV 195.1M
- PBYI 171.7M
- IPO Year
- SRV N/A
- PBYI N/A
- Fundamental
- Price
- SRV $44.91
- PBYI $4.45
- Analyst Decision
- SRV
- PBYI Strong Buy
- Analyst Count
- SRV 0
- PBYI 1
- Target Price
- SRV N/A
- PBYI $7.00
- AVG Volume (30 Days)
- SRV 33.9K
- PBYI 684.0K
- Earning Date
- SRV 01-01-0001
- PBYI 11-06-2025
- Dividend Yield
- SRV 13.38%
- PBYI N/A
- EPS Growth
- SRV N/A
- PBYI 434.29
- EPS
- SRV N/A
- PBYI 0.97
- Revenue
- SRV N/A
- PBYI $238,062,000.00
- Revenue This Year
- SRV N/A
- PBYI N/A
- Revenue Next Year
- SRV N/A
- PBYI N/A
- P/E Ratio
- SRV N/A
- PBYI $4.60
- Revenue Growth
- SRV N/A
- PBYI 8.63
- 52 Week Low
- SRV $30.73
- PBYI $2.32
- 52 Week High
- SRV $44.30
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- SRV 69.06
- PBYI 45.26
- Support Level
- SRV $43.67
- PBYI $4.49
- Resistance Level
- SRV $44.51
- PBYI $5.22
- Average True Range (ATR)
- SRV 0.51
- PBYI 0.26
- MACD
- SRV 0.09
- PBYI -0.13
- Stochastic Oscillator
- SRV 98.55
- PBYI 5.34
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.